A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment.

Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget (2017) 0.78

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases. Oncoimmunology (2017) 0.75

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. Front Immunol (2017) 0.75

Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol (2016) 0.75

Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. Vaccines (Basel) (2016) 0.75

Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. Vaccines (Basel) (2016) 0.75

Metabolic Reprogramming in the Tumour Microenvironment: a Hallmark Shared by Cancer Cells and T Lymphocytes. Immunology (2017) 0.75

Elimination of GPR146-mediated antiviral function through IRF3/HES1-signaling pathway. Immunology (2017) 0.75

Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer (2017) 0.75

Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol (2017) 0.75

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00

International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90

Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80

HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12

Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene (2009) 8.01

Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer (2004) 7.91

Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell (2010) 7.20

Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 6.91

Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature (2002) 6.50

HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 5.99

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71

Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 4.28

A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25

Purinergic signaling during inflammation. N Engl J Med (2012) 4.08

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07

Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest (2002) 4.05

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest (2013) 3.55

T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol (2006) 3.40

Interdependence of hypoxic and innate immune responses. Nat Rev Immunol (2009) 3.29

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 2.95

Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood (2004) 2.80

Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J (2007) 2.72

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67

Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol (2001) 2.63

Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 2.59

Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J (2000) 2.53

HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood (2008) 2.52

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50

The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol (2005) 2.43

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37

Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature (2014) 2.37

Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol (2005) 2.36

Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis (1993) 2.19

CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13

Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol (2011) 2.05

CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03

Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol (2007) 2.03

Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol (2014) 1.96

The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res (1997) 1.95

Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol (2006) 1.93

Adenosine receptors in regulation of dendritic cell differentiation and function. Blood (2008) 1.91

New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78

Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med (1997) 1.75

Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 1.75

Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov (2013) 1.74

Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease. Blood (2012) 1.72

Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A (2012) 1.70

Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol (2008) 1.69

CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69

Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66

Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60

HIF transcription factors, inflammation, and immunity. Immunity (2014) 1.55

HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer (2009) 1.54

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54

CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 1.52

CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52

Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol (2002) 1.50

Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res (1986) 1.50

Inflammatory hypoxia: role of hypoxia-inducible factor. Cell Cycle (2005) 1.50

Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol (2007) 1.47

Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol (2011) 1.45

Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2002) 1.44

Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia (2008) 1.43

Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med (2015) 1.42

Inflammation and immune surveillance in cancer. Semin Cancer Biol (2011) 1.41

Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J (2011) 1.38

CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38

Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proc Natl Acad Sci U S A (2005) 1.38

High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med (2000) 1.38

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36

Ecto-5'-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol (2006) 1.35

Control of IFN-alphaA by CD73: implications for mucosal inflammation. J Immunol (2008) 1.34

Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol (2007) 1.32

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A (2013) 1.32

RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis (2007) 1.29

Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28

A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol (2009) 1.27

Culturing at atmospheric oxygen levels impacts lymphocyte function. Proc Natl Acad Sci U S A (2005) 1.23

Divergent effects of hypoxia on dendritic cell functions. Blood (2008) 1.20

The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol (2012) 1.18

Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J Neurochem (2000) 1.17

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother (2011) 1.16

Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol (2013) 1.14

Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res (2006) 1.13

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res (2014) 1.09

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother (2011) 1.09

The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem (2008) 1.08

Enhanced airway reactivity and inflammation in A2A adenosine receptor-deficient allergic mice. Am J Physiol Lung Cell Mol Physiol (2007) 1.07

Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol (2012) 1.07

Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol (2008) 1.07

Enhanced interferon-gamma gene expression in T Cells and reduced ovalbumin-dependent lung eosinophilia in hypoxia-inducible factor-1-alpha-deficient mice. Int Arch Allergy Immunol (2009) 1.05